Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Ocular Therapeutix's operating cash flow for the twelve months ending Jun 30, 2026 was -$238.24M. For fiscal 2025 it was -$204.88M. The highest annual figure on record is -$12.59M in fiscal 2012.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$204.88M | – |
| FY2024 | Dec 31, 2024 | -$134.68M | – |
| FY2023 | Dec 31, 2023 | -$70.23M | – |
| FY2022 | Dec 31, 2022 | -$59.60M | – |
| FY2021 | Dec 31, 2021 | -$65.55M | – |
| FY2020 | Dec 31, 2020 | -$53.55M | – |
| FY2019 | Dec 31, 2019 | -$77.58M | – |
| FY2018 | Dec 31, 2018 | -$49.23M | – |
| FY2017 | Dec 31, 2017 | -$50.47M | – |
| FY2016 | Dec 31, 2016 | -$34.00M | – |
| FY2015 | Dec 31, 2015 | -$33.74M | – |
| FY2014 | Dec 31, 2014 | -$20.50M | – |
| FY2013 | Dec 31, 2013 | -$12.65M | – |
| FY2012 | Dec 31, 2012 | -$12.59M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$67.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$65.99M | – |
| Q4 FY2025 | Dec 31, 2025 | -$54.25M | – |
| Q3 FY2025 | Sep 30, 2025 | -$50.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$55.24M | – |
| Q1 FY2025 | Mar 31, 2025 | -$44.67M | – |
| Q4 FY2024 | Dec 31, 2024 | -$39.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$36.56M | – |
| Q2 FY2024 | Jun 30, 2024 | -$24.80M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.89M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.45M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.73M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.08M | – |
| Q1 FY2023 | Mar 31, 2023 | -$19.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$16.96M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.17M | – |
| Q2 FY2022 | Jun 30, 2022 | -$10.88M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.60M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.15M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.98M | – |
| Q2 FY2021 | Jun 30, 2021 | -$20.06M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.25M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.66M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.85M | – |
| Q4 FY2019 | Dec 31, 2019 | -$19.47M | – |
| Q3 FY2019 | Sep 30, 2019 | -$19.54M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.18M | – |
| Q1 FY2019 | Mar 31, 2019 | -$19.39M | – |
| Q4 FY2018 | Dec 31, 2018 | -$13.65M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.87M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.23M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.47M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.38M | – |
| Q3 FY2017 | Sep 30, 2017 | -$14.38M | – |
| Q2 FY2017 | Jun 30, 2017 | -$11.13M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.58M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.61M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.33M | – |
See a number that looks wrong?